



(51) International Patent Classification:
C07D 223/08 (2006.01) *A61P 35/00* (2006.01)
A61K 31/55 (2006.01)

(21) International Application Number:
PCT/SE2012/000158

(22) International Filing Date:
15 October 2012 (15.10.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1100776-2 19 October 2011 (19.10.2011) SE
1200303-4 16 May 2012 (16.05.2012) SE

(71) Applicant (for all designated States except US):
VIVOLUX AB [SE/SE]; Hus Oscar II, Uppsala Science
Park, S-75183 Uppsala (SE).

(72) Inventors; and

(71) Applicants (for US only): **LINDER, Stig** [SE/SE]; Attun-
davägen 4, S-16858 Bromma (SE). **LARSSON, Rolf**
[SE/SE]; Hävelvägen 2, S-75647 Uppsala (SE).


(74) Agent: **CONIMAR AB**; Box 2086, S-14102 Huddinge
(SE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

[Continued on next page]

(54) Title: METHOD FOR INHIBITION OF DEUBIQUITINATING ACTIVITY



(57) Abstract: A compound of the general structure (I) is capable of abrogating the deubiquitinating (DUB) activity of the 19S RP DUBs. The compound can be used for treating cancer, in particular of cancer refractory to treatment by state-of-the-art chemotherapy. Also disclosed are corresponding methods of treatment and a pharmaceutical composition comprising the compound.




Fig. 1a



TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). **Published:**

— *with international search report (Art. 21(3))*

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*